RankAlpha logo
Back to Rankings

AMLX

AmylyxD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bullish case is that completed LUCIDITY enrollment de-risks execution, prior avexitide studies showed statistically significant hypoglycemia reductions, and the reported cash runway into 2028 gives AMLX enough time to reach its main value-defining readout without obvious immediate financing stress [#8-K-2026-03-24] [#10-K-2026-03-03].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.5.
What can break
AMLX remains heavily dependent on a successful Phase 3 avexitide outcome, making the setup binary despite multiple programs.
Momentum
12
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $24.00 · Bear $9.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $22.33
Why
Momentum12 · Δ7d +2.5
Value41 · Δ7d +0.1
Sentiment73 · Δ7d -0.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
12
34% active weight
Current posture
7d trendImproving
Δ7d
+2.5
Δ21d
-61.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
73
33% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+15.1
Why this grade

Composite grade D. Momentum 11.8 / Value 41.1 / Sentiment 73.4

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.48B
Beta
-0.30
Shares Out
109.82M
P/E (TTM) · Derived
-8.8
P/S (TTM)
3249.71
P/FCF (TTM) · Derived
-7.33
Rev YoY
-100.0%
EPS YoY
+65.5%
Gross Margin
-94.5%
Op Margin
-47349.8%
Net Debt
-$176.5M
Current Ratio
13.70
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology